Compare · BDRX vs NVO
BDRX vs NVO
Side-by-side comparison of Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $194.45B, about 100648.6x BDRX ($1.9M).
- Over the past year, BDRX is down 92.4% and NVO is down 41.4% - NVO leads by 51.0 points.
- NVO has hit the wire 4 times in the past 4 weeks while BDRX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 1 for BDRX).
- Company
- Biodexa Pharmaceuticals plc American Depositary Shs
- Novo Nordisk A/S
- Price
- $3.06-3.47%
- $43.57-0.76%
- Market cap
- $1.9M
- $194.45B
- 1M return
- -5.85%
- -2.57%
- 1Y return
- -92.36%
- -41.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BDRX
- Amendment: SEC Form SCHEDULE 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs
- SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs
- Biodexa issues letter to Shareholders
- SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
- SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
- SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
- SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
- SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
- SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
- Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S